Vanda Pharmaceuticals Inc.
NASDAQVanda Pharmaceuticals enters the post-Q1 stretch having just delivered a messy earnings print — but with a guidance raise that gives the bulls something to work with. The company reported Q1 EPS of -$0.82, missing the -$0.69 consensus by $0.13. Revenue of $51.7M fell short of the $55.0M estimate. Those are not trivial misses. Yet Vanda simultaneously raised full-year 2026 sales…
Snapshot as of 7 May 2026
Vanda Pharmaceuticals enters the post-Q1 stretch having just delivered a messy earnings print — but with a guidance raise that gives the bulls something to work with. The company reported Q1 EPS of -$0.82, missing the…
Vanda Pharmaceuticals heads into its May 6 Q1 results carrying the heaviest short interest build of the past two months — and a history of double-digit post-earnings drops that will keep every positioning decision…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VNDA — free to start on ORTEX.
Sign up for free →Open VNDA on ORTEX